Trial Profile

A Phase III Study of Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia in Children

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 17 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eltrombopag (Primary) ; Anti-D Rh0 immunoglobulin; Immune globulin; Prednisolone; Prednisone
Indications Idiopathic thrombocytopenic purpura
Focus Therapeutic Use
Acronyms PINES

Most Recent Events

10 Dec 2024 Status changed from active, no longer recruiting to discontinued, According to a results presented at the 66th American Society of Hematology Annual Meeting and Exposition
10 Dec 2024 According to a results presented at the 66th American Society of Hematology Annual Meeting and Exposition, trial accrual was closed early for efficacy per DSMB recommendation.
26 Mar 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com